SCHEMBL2964598

SCHEMBL2964598

CCOC(=O)c1ccc2c(c1)ncn2-c1cccc(C(OC)c2nccn2C)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.48
HPGD P15428 8/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977158 0.86 FGFR1 (0.48) FGFR1HPGDSMN1; SMN2MAPK1KMT2A
SCHEMBL2652173 0.85 FGFR1 (0.50) FGFR1HPGDSMN1; SMN2MAPK1KMT2A
SCHEMBL2969712 0.84 GABRA1 (0.51) FGFR1HPGDSMN1; SMN2MAPK1KMT2A
SCHEMBL2966478 0.84 FGFR1 (0.52) FGFR1HPGDSMN1; SMN2MAPK1KMT2A
SCHEMBL2965033 0.83 FGFR1 (0.48) FGFR1HPGDSMN1; SMN2MAPK1KMT2A
SCHEMBL2977437 0.83 FGFR1 (0.48) FGFR1HPGDSMN1; SMN2MAPK1KMT2A
SCHEMBL2974090 0.82 HPGD (0.38) FGFR1HPGDSMN1; SMN2MAPK1
SCHEMBL2976802 0.81 GABRP (0.39) FGFR1HPGDSMN1; SMN2MAPK1GABRA1
SCHEMBL2652694 0.78 HPGD (0.37) FGFR1HPGDSMN1; SMN2MAPK1GABRA1
SCHEMBL1881907 0.78 NOTUM (0.50) HPGDKMT2AMEN1ALDH1A1GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 FGFR1 4324/4885HPGD 1855/4885SMN1; SMN2 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.